Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects

Journal of Medicinal Chemistry

Volumn 46, Issue 2, 2003, Pages 222-236

  Mettey, Yvette ^a   Gompel, Marie ^b   Thomas, Virginie ^b   Garnier, Matthieu ^b   Leost, Maryse ^b   Ceballos Picot, Irène ^c   Noble, Martin ^d   Endicott, Jane ^d   Vierfond, Jean Michel ^a   Meijer, Laurent ^b  

^a Faculte de Medicine et de Pharmacie   (France)

^b STATION BIOLOGIQUE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOISINE DERIVATIVE; CYCLIN A; CYCLIN B; CYCLIN C; CYCLIN D; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLINE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN P25; PYRAZINE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; COMPETITIVE INHIBITION; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG BINDING SITE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CDC2 PROTEIN KINASE; CDC2-CDC28 KINASES; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEURONS; PROTEIN-SERINE-THREONINE KINASES; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037448375     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020319p     Document Type: Article

References (84)

1. Adams, J. L.; Lee, D. Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases. Curr. Opin. Drug Discovery Dev. 1999, 2, 96-109.
2. Garcia-Echeverria, C.; Traxler, P.; Evans, D. B. ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev. 2000, 20, 28-57.
3. Sridhar, R.; Hanson-Painton, O.; Cooper, D. R. Protein kinases as therapeutic targets. Pharm. Res. 2000, 17, 1345-1353.
4. Dumas, J. Protein kinase inhibitors: emerging pharmacophores 1997-2000. Exp. Opin. Ther. Patents 2001, 11, 405-429.
5. Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. 1997, 13, 261-291.
6. Pavletich, N. P. Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 1999, 287, 821-828.
7. Malumbres, M.; Ortega, S.; Barbacid, M. Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biol. Chem. 2000, 381, 827-838.
8. Nikolic, M.; Tsai, L. H. Activity and regulation of p35/Cdk5 kinase complex. Methods Enzymol. 2000, 325, 200-213.
9. Maccioni, R. B.; Otth, C.; Concha, I. I.; Munoz, J. P. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur. J. Biochem. 2001, 268, 1518-1527.
10. Dhavan, R.; Tsai, L.-H. A decade of CDK5. Nature Rev. Mol. Cell Biol. 2001, 2, 749-759.
11. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nature Rev. Cancer 2001, 1, 222-231.
12. Dominguez, I.; Green, J. B. Missing links in GSK3 regulation. Dev. Biol. 2001, 15, 303-313.
13. Harwood, A. J. Regulation of GSK-3: a cellular multiprocessor. Cell 2001, 29, 821-824.
14. Cohen, P.; Frame, S. The renaissance of GSK3. Nature Rev. Mol. Cell Biol. 2001, 2, 769-776.
15. Frame, S.; Cohen, P. GSK3 takes center stage more than 20 years after its discovery. Biochem. J. 2001, 359, 1-16.
16. Grimes, C. A.; Jope, R. S. The multifaceted roles of glycogen synthase kinase 3 in cellular signaling. Prog. Neurobiol. 2001, 65, 391-426.
17. Eldar-Finkelman, H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 2002, 8, 126-132.
18. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitorsof cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
19. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J. Y.; Détivaud, L.; Leclerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine derivatives. Eur. J. Biochem. 1994, 224, 771-786.
20. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J. P. J.; Blow, J. J.; Inagaki, N.; Inagaki, M.; Delcros, J. G.; Moulinoux, J. P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997, 243, 527-536.
21. de Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
22. Gray, N.; Wodicka, L.; Thunnissen, A. M.; Norman, T.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; Leclerc, S.; Meijer, L.; Kim, S. H.; Lockhart, D. J.; Schultze, P. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors. Science 1998, 281, 533-538.
23. Chang, Y. T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
24. Brooks, E. E.; Gray, N. S.; Joly, A.; Kerwar, S. S.; Lum, R.; Mackman, R. L.; Norman, T. C.; Rosete, J.; Rowe, M.; Schow, S. R.; Schultz, P. G.; Wang, X.; Wick, M. M.; Shiffman, D. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 1997, 272, 29207-29211.
25. Legraverend, M.; Noble, M.; Tunnah, P.; Ducrot, P.; Ludwig, O.; Leclerc, S.; Grierson, D. S.; Meijer, L.; Endicott, J. Cyclin-dependent kinase inhibition by new C-2 alkylynated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 2000, 43, 1282-1292.
26. Dreyer, M. K.; Borcherding, D. R.; Dumont, J. A.; Peet, N. P.; Tsay, J. T.; Wright, P. S.; Bitonti, A. J.; Shen, J.; Kim, S. H. Crystal structure ofhuman cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 2001, 44, 524-530.
27. Arris, C. E.; Boyle, F. T.; Calvert, A. H.; Curtin, N. J.; Endicott, J. A.; Garman, E. F.; Gibson, A. E.; Golding, B. T.; Grant, B. T.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Lawrie, A. M.; Newell, D. R.; Noble, M. E. M.; Sausville, E. A.; Schultz, R.; Yu, W. Identification of novel purine and pyrimidine cycline-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 2000, 43, 2797-2804.
28. Shum, P. W.; Peet, N. P.; Weintraub, P. M.; Le, T. B.; Zhao, Z.; Barbone, F.; Cashman, B.; Tsay, J.; Dwyer, S.; Loos, P. C.; Powers, E. A.; Kropp, K.; Wright, P. S.; Bitonti, A.; Dumont, J.; Borcherding, D. R. The design and synthesis of purine inhibitors of CDK2. III. Nucleosides Nucleotides Nucleic Acids 2001, 20, 1067-1078.
29. Park, S. G.; Cheon, J. Y.; Lee, Y. H.; Park, J. S.; Lee, K. Y.; Lee, C. H.; Lee, S. K. A specific inhibitor of cyclin-dependent protein kinases, CDC2 and CDK2. Mol. Cells 1996, 6, 679-683.
30. Sedlacek, H. H. Mechanism of action of flavopiridol. Crit. Rev. Oncol./Hematol. 2001, 38, 139-170.
31. Hoessel, R.; Leclerc, S.; Endicott, J.; Noble, M.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol. 1999, 1, 60-67.
32. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Mandelkow, E.-M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease - A property common to most CDK inhibitors? J. Biol. Chem. 2001, 276, 251-260.
33. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A.; Meijer, L.; Kunick, C. The paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 1999, 42, 2909-2919.
34. Zaharevitz, D.; Gussio, R.; Leost, M.; Senderowicz, A. M.; Lahusen, T.; Kunick, C.; Meijer, L.; Sausville, E. A. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 1999, 59, 2566-2569.
35. Leost, M.; Schultz, C.; Link, A.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderovitz, A.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267, 5983-5994.
36. Kitagawa, M.; Okabe, T.; Ogino, H.; Matsumoto, H.; Suzuki- Takahashi, I.; Kokubo, T.; Higashi, H.; Saitoh, S.; Taya, Y.; Yasuda, H.; Ohba, Y.; Nishimura, S.; Tanaka, N.; Okuyama, A. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 1993, 8, 2425-2432.
37. Meijer, L.; Thunissen, A. M. W. H.; White, A.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S.-H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3β and casein kinase 1 by hymenialdisine, a marine sponge constituent. Chem., Biol. 2000, 7, 51-63.
38. Nugiel, D. A.; Etzkorn, A. M.; Vidwans, A.; Benfield, P. A.; Boisclair, M.; Burton, C. R.; Cox, S.; Czerniak, P. M.; Doleniak, D.; Seitz, S. P. Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors. J. Med. Chem. 2001, 44, 1334-1336.
39. Zimmermann, J. (Ciba-Geigy). Pharmacologically active pyrimidine derivatives and processes for the preparation thereof. PCT WO 95/09853, 1995.
40. Barvian, M.; Boschelli, D. H.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido [2,3-d] pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2000, 43, 4606-4616.
41. Clare, P. M.; Poorman, R. A.; Kelley, L. C.; Watenpaugh, K. D.; Bannow, C. A.; Leach, K. L. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism. J. Biol. Chem. 2001, 276, 48292-48299.
42. Kent, L. L.; Hullcampbell, N. E.; Lau, T.; Wu, J. C.; Thompson, S. A.; Nori, M. Characterization of novel inhibitors of cyclin-dependent kinases. Biochem. Biophys. Res. Commun. 1999, 260, 768-774.
43. Davis, S. T.; Benson, B. G.; Bramson, H. N.; Chapman, D. E.; Dickerson, S. H.; Dold, K. M.; Eberwein, D. J.; Edelstein, M.; Frye, S. V.; Gampe, R. T.; Griffin, R. J.; Harris, P. A.; Hassell, A. M.; Holmes, W. D.; Hunter, R. N.; Knick, V. B.; Lackey, K.; Lovejoy, B.; Luzzio, M. J.; Murray, D.; Parker, P.; Rocque, W. J.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001, 291, 134-137.
44. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis. J. Med. Chem. 2001, 44, 4339-4358.
45. Fry, D. W.; Harvey, P. H.; Bedford, D.; Fritsch, A.; Keller, P. R., Wu, Z.; Dobrusin, E.; Leopold, W. R.; Fattaey, A.; Garrett, M. D. Cell cycle and biochemical effects of PD0183812, a potent inhibitor of cyclin-dependent kinase 4. J. Biol. Chem. 2001, 276, 16617-16623.
46. Jeong, H. W.; Kim, M. R. R.; Son, K. H.; Han, M. Y.; Ha, J. H.; Garnier, M.; Meijer, L.; Kwon, B. M. Cinnamaldehydes inhibit cyclin-dependent kinase 4/cyclin Dl. Bioorg. Med. Chem. Lett. 2000, 10, 1819-1822.
47. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43, 133-138.
48. Sielecki, T. M.; Johnson, T. L.; Liu, J.; Muckelbauer, J. K.; Grafstrom, R. H.; Cox, S.; Boylan, J.; Burton, C. R.; Chen, H.; Smallwood, A.; Chang, C. H.; Boisclair, M.; Benfield, P. A.; Trainor, G. L.; Seitz, S. P. Quinazolines as cyclin dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1157-1160.
49. Soni, R.; O'Reilly, T.; Furet, P.; Muller, L.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Fabbro, D.; Chaudhuri, B. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Inst. 2001, 21, 436-446.
50. Lane, M. E.; Yu, B.; Rice, A.; Lipson, K. E.; Liang, C.; Sun, L.; Tang, C.; McMahon, G.; Pestell, R. G.; Wadler, S. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001, 61, 6170-6177.
51. Carini, D. J.; Kaltenbach, R. F.; Liu, J.; Benfield, P. A.; Boylan, J.; Boisclair, M.; Brizuela, L.; Burton, C. R.; Cox, S.; Grafstrom, R.; Harrison, B. A.; Harrison, K.; Akamike, E.; Markwalder, J. A.; Nakano, Y.; Seitz, S. P.; Sharp, D. M.; Trainor, G. L.; Sielecki, T. M. Identification of selective inhibitors of cyclin dependent kinase 4. Bioorg. Med. Chem. Lett. 2001, 11, 2209-2211.
52. Kim, K. S.; Kimball, S. D.; Misra, R. N.; Rawlins, D. B.; Hunt, J. T.; Xiao, H. Y.; Lu, S.; Qian, L.; Han, W. C.; Shan, W.; Mitt, T.; Cai, Z. W.; Poss, M. A.; Zhu, H.; Sack, J. S.; Tokarski, J. S.; Chang, C. Y.; Pavletich, N.; Kamath, A.; Humphreys, W. G.; Marathe, P.; Bursuker, I.; Kellar, K. A.; Roongta, U.; Batorsky, R.; Mulheron, J. G.; Bol, D.; Fairchild, C. R.; Lee, F. Y.; Webster, K. R. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J. Med. Chem. 2002, 45, 3905-3927.
53. Toogood, P. L. Cyclin-dependent kinase inhibitors for treating cancer. Med. Res. Rev. 2001, 21, 487-498.
54. Gray, N.; Détivaud, L.; Doerig, C.; Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6, 859-876.
55. Fischer, P. M.; Lane, D. P. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. 2000, 7, 1213-1245.
56. Pestell, R.; Mani, S.; Wange, C.; Wu, K.; Francis, R. Cyclin-dependent kinase inhibitors: novel anticancer agents. Exp. Opin. Investig. Drugs 2000, 9, 1849-1870.
57. Rosiana, G. R.; Chang, Y. T. Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors. Exp. Opin. Ther. Patents 2000, 10, 1-16.
58. Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 2000, 43, 1-18.
59. Kaubisch, A.; Schwartz G. K. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development. Cancer J. 2000, 6, 192-212.
60. Coghlan, M. P.; Culbert, A. A.; Cross, D. A. E.; Corcoran, S. L.; Yates, J. W.; Pearce, N. J.; Rausch, O. L.; Murphy, G. J.; Carter, P. S.; Cox, L. R.; Mills, D.; Brown, M. J.; Haigh, D.; Ward, R. W.; Smith, D. G.; Murray, K. J.; Reith, A. D.; Holder, J. C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7, 793-803.
61. Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haigh, D.; Ife, R. J.; Saunders, M.; Slingsby, B. P.; Stacey, R.; Ward, R. W. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2001, 11, 635-639.
62. Ryves, W. J.; Harwood, A. J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 2001, 280, 720-725.
63. Vierfond, J. M.; Mettey, Y.; Mascrier-Demagny, L.; Miocque, M. Cyclisation par amination intramoléculaire dans la série de la pyrazine. Tetrahedron Lett. 1981, 22, 1219-1222.
64. Davis, M. L.; Wakefield, B. J.; Wardell, J. A. Reactions of β-(lithiomethyl)azines with nitriles as a route to pyrrolo-pyridines, -quinolines, -pyrazines, -quinoxalines and -pyrimidines. Tetrahedron 1992, 48, 939-952.
65. De Bondt, H. L.; Rosenblatt, J.; Jancarik, J.; Jones, H. D.; Morgan, D. O.; Kim, S. H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363, 595-602.
66. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim S. H. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins: Struct., Funct. Genet. 1995, 22, 378-391.
67. de Azevedo, W. F.; Mueller-Dieckmann, H.-J.; Schultze-Gahmen, U.; Worland, P. J.; Sausville, E.; Kim, S.-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2735-2740.
68. Lawrie, A. M.; Noble, M. E.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 1997, 4, 796-800.
69. Russo, A. A.; Jeffrey, P. D.; Pavletich, N. P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 1996, 3, 696-700.
70. Meijer, L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 1996, 6, 393-397.
71. Knockaert, M.; Gray, N.; Damiens, E.; Chang, Y. T.; Grellier, P.; Grant, K.; Fergusson, D.; Mottram, J.; Soete, M.; Dubremetz, J. F.; LeRoch, K.; Doerig, C.; Schultz, P. G.; Meijer, L. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem. Biol. 2000, 7, 411-422.
72. Knockaert, M.; Viking, K.; Schmitt, S.; Leost, M.; Mottram, J.; Kunick, C.; Meijer, L. Intracellular targets of paullones: identification by affinity chromatography using immobilized inhibitor. J. Biol. Chem. 2002, 277, 25493-25501.
73. Diehl, J. A.; Cheng, M.; Roussel, M. F.; Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12, 3499-3511.
74. Rosenblatt, J.; De, Bondt H.; Jancarik, J.; Morgan, D. O.; Kim, S. H. Purification and crystallization of human cyclin-dependent kinase 2. J. Mol. Biol. 1993, 230, 1317-1319.
75. Brown, N. R.; Noble, M. E. M.; Lawrie, A. M.; Morris, M. C.; Tunnah, P.; Divita, G.; Johnson, L. N.; Endicott, J. A. Effects of phosphorylation of threonine 160 on CDK2 structure and activity. J. Biol. Chem. 1999, 274, 8746-8756.
76. Leslie, A. G. W. Joint CCP4 and ESF-EAMCB Newsletter on Protein Crystallography. 1992, Vol. 26.
77. CCP4. The CCP4 (Collaborative Computational Project Number 4) suite: Programs for protein crystallography. Acta Crystallogr. D 1994, 50, 760-763.
78. Navaza, J. AMoRe: An automated package for molecular replacement. Acta Crystallogr. 1994, A50, 157-163.
79. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 1997, 53, 240-255.
80. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 1991, 47, 110-119.
81. Lamzin, V. S.; Wilson, K. S. Automated refinement of protein models. Acta Crystallogr. D 1993, 49, 129-147.
82. Pleasure, S. J.; Page, C.; Lee, V. M. Y. Pure, post-mitotic polarized human neurons derived from NT2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J. Neurosci. 1992, 12, 1802-1815.
83. Saillé, C.; Marin, P.; Martinou, J. C.; Nicole, A.; London, J.; Ceballos-Picot, I. Transgenic murine cortical neurons expressing human bcl-2 exhibit increased resistance to amyloid beta-peptide neurotoxicity. Neuroscience 1999, 92, 1455-1463.
84. Damiens, E.; Baratte, B.; Marie, D.; Eisenbrand, G.; Meijer, L. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 2001, 20, 3786-3797.